Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Infliximab versus vedolizumab in treating immune-mediated diarrhea and colitis

Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the preliminary findings of a randomized controlled trial (NCT04407247) comparing infliximab and vedolizumab in patients with immune-mediated diarrhea and colitis (IMDC). Both treatments showed similar high remission rates at two weeks and symptom improvement typically within three days. Most patients achieved steroid-free remission at one month, with a few experiencing symptom recurrence. Both drugs exhibited comparable safety profiles with mainly mild adverse events. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.